162 related articles for article (PubMed ID: 26780078)
1. [Efficacy and safety of antivascular drugs after anti-EFGR: aflibercept after cetuximab, a clinical case].
Aroldi F; Zaniboni A
Recenti Prog Med; 2015 Dec; 106(12):653e-6e. PubMed ID: 26780078
[TBL] [Abstract][Full Text] [Related]
2. [Late complete response after long remission from treatment with FOLFIRI-aflibercept for metastatic colorectal cancer after progression to FOLFOX-bevacizumab].
De Divitiis C; Cassata A; Nasti G; Ottaiano A; Nappi A; Barretta ML; Iaffaioli RV
Recenti Prog Med; 2015 Aug; 106(8):e407-13. PubMed ID: 26228865
[TBL] [Abstract][Full Text] [Related]
3. Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy.
Ruff P; Ferry DR; Lakomỳ R; Prausová J; Van Hazel GA; Hoff PM; Cunningham D; Arnold D; Schmoll HJ; Moiseyenko VM; McKendrick JJ; Ten Tije AJ; Vishwanath RL; Bhargava P; Chevalier S; Macarulla T; Van Cutsem E
Eur J Cancer; 2015 Jan; 51(1):18-26. PubMed ID: 25466509
[TBL] [Abstract][Full Text] [Related]
4. Aflibercept for metastatic colorectal cancer: safety data from the Spanish named patient program.
Salgado Fernández M; Pérez Hoyos MT; Díaz de Corcuera I; Vidal Arbués A; García de la Torre M
Expert Opin Drug Saf; 2015 Aug; 14(8):1171-9. PubMed ID: 26076885
[TBL] [Abstract][Full Text] [Related]
5. Complete Response to Aflibercept-FOLFIRI in One Patient With Colorectal Cancer Refractory to Bevacizumab-FOLFOX: A Possible Autocrine Vascular Endothelial Growth Factor Receptor 2-Related Mechanism.
Kim S; Cayre A; Jary M; Jacquin M; Arbez-Gindre F; Fein F; Lakkis Z; Nguyen T; Borg C
Clin Colorectal Cancer; 2016 Dec; 15(4):e229-e234. PubMed ID: 27600470
[No Abstract] [Full Text] [Related]
6. [Treatment with FOLFIRI plus aflibercept in a patient with RAS and BRAF wild-type, right-sided colon cancer and potentially resectable liver metastases].
Pietrantonio F
Recenti Prog Med; 2018 Nov; 109(11):20e-23e. PubMed ID: 30565583
[TBL] [Abstract][Full Text] [Related]
7. Conversion chemotherapy using cetuximab plus FOLFIRI followed by bevacizumab plus mFOLFOX6 in patients with unresectable liver metastases from colorectal cancer.
Uehara K; Ishiguro S; Hiramatsu K; Nishio H; Takeuchi E; Takahari D; Yoshioka Y; Takahashi Y; Ebata T; Yoshimura K; Muro K; Nagino M
Jpn J Clin Oncol; 2011 Oct; 41(10):1229-32. PubMed ID: 21840871
[TBL] [Abstract][Full Text] [Related]
8. Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Taieb J; Tabernero J; Mini E; Subtil F; Folprecht G; Van Laethem JL; Thaler J; Bridgewater J; Petersen LN; Blons H; Collette L; Van Cutsem E; Rougier P; Salazar R; Bedenne L; Emile JF; Laurent-Puig P; Lepage C;
Lancet Oncol; 2014 Jul; 15(8):862-73. PubMed ID: 24928083
[TBL] [Abstract][Full Text] [Related]
9. Second-line chemotherapy with fluorouracil, leucovorin, and irinotecan (FOLFIRI regimen) in patients with advanced small bowel adenocarcinoma after failure of first-line platinum-based chemotherapy: a multicenter AGEO study.
Zaanan A; Gauthier M; Malka D; Locher C; Gornet JM; Thirot-Bidault A; Tougeron D; Taïeb J; Bonnetain F; Aparicio T;
Cancer; 2011 Apr; 117(7):1422-8. PubMed ID: 21425142
[TBL] [Abstract][Full Text] [Related]
10. [Efficacy of CPT-11 combined 5-FU/CF (FOLFIRI) regimen on advanced colorectal cancer].
Luo HY; Li YH; Zhang L; Jiang WQ; Shi YX; Wang F; He YJ; Xu RH
Ai Zheng; 2007 Aug; 26(8):905-8. PubMed ID: 17697557
[TBL] [Abstract][Full Text] [Related]
11. Multiorgan failure in a patient treated with the 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan regimen.
Schwartzman AD; Sethi R; Smith R
Clin Colorectal Cancer; 2013 Jun; 12(2):136-9. PubMed ID: 23098664
[No Abstract] [Full Text] [Related]
12. Colon cancer, version 3.2014.
Benson AB; Venook AP; Bekaii-Saab T; Chan E; Chen YJ; Cooper HS; Engstrom PF; Enzinger PC; Fenton MJ; Fuchs CS; Grem JL; Hunt S; Kamel A; Leong LA; Lin E; Messersmith W; Mulcahy MF; Murphy JD; Nurkin S; Rohren E; Ryan DP; Saltz L; Sharma S; Shibata D; Skibber JM; Sofocleous CT; Stoffel EM; Stotsky-Himelfarb E; Willett CG; Gregory KM; Freedman-Cass DA;
J Natl Compr Canc Netw; 2014 Jul; 12(7):1028-59. PubMed ID: 24994923
[TBL] [Abstract][Full Text] [Related]
13. Pseudocirrhosis after anti-EGFR-based neoadjuvant therapy for hepatic metastasis from colon cancer: a different point of view.
Battisti S; Guida FM; Pagliara E; Tonini G; Zobel BB; Santini D
Clin Colorectal Cancer; 2014 Sep; 13(3):e13-5. PubMed ID: 25085312
[No Abstract] [Full Text] [Related]
14. [A case of colon cancer with multiple lung metastases responding completely to FOLFIRI and FOLFOX therapy].
Kume S; Takahashi M; Kubota T; Hirata T; Torigoe Y; Ikeda O; Goto Y
Gan To Kagaku Ryoho; 2010 Sep; 37(9):1809-12. PubMed ID: 20841953
[TBL] [Abstract][Full Text] [Related]
15. Clinical and radiological response with FOLFOXIRI and bevacizumab as third-line therapy after mFOLFOX6 and FOLFIRI failure.
de Melo JV; Vieira de Melo MS; Abad MH
Anticancer Drugs; 2011 Jun; 22 Suppl 2():S19-20. PubMed ID: 21768793
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy and safety of bevacizumab (BEV) plus chemotherapeutic agents in the treatment of metastatic colorectal cancer, mCRC].
Guo X; Liu TS; Yu YY; Zhou YH; Chen Y; Zhuang RY; Cui YH
Zhonghua Zhong Liu Za Zhi; 2013 Aug; 35(8):604-7. PubMed ID: 24314219
[TBL] [Abstract][Full Text] [Related]
17. [Chemotherapy of colonic cancer].
Block S
Soins; 2010 Mar; (743):46. PubMed ID: 20423037
[No Abstract] [Full Text] [Related]
18. Clinical outcome of elderly patients with metastatic colorectal cancer treated with FOLFOXIRI versus FOLFIRI: Subgroup analysis of a randomized phase III trial from the Hellenic Oncology Research Group (HORG).
Vamvakas L; Athanasiadis A; Karampeazis A; Kakolyris S; Polyzos A; Kouroussis Ch; Ziras N; Kalbakis K; Georgoulias V; Souglakos J
Crit Rev Oncol Hematol; 2010 Oct; 76(1):61-70. PubMed ID: 19729318
[TBL] [Abstract][Full Text] [Related]
19. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
Van Cutsem E; Tabernero J; Lakomy R; Prenen H; Prausová J; Macarulla T; Ruff P; van Hazel GA; Moiseyenko V; Ferry D; McKendrick J; Polikoff J; Tellier A; Castan R; Allegra C
J Clin Oncol; 2012 Oct; 30(28):3499-506. PubMed ID: 22949147
[TBL] [Abstract][Full Text] [Related]
20. Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial.
Tabernero J; Van Cutsem E; Lakomý R; Prausová J; Ruff P; van Hazel GA; Moiseyenko VM; Ferry DR; McKendrick JJ; Soussan-Lazard K; Chevalier S; Allegra CJ
Eur J Cancer; 2014 Jan; 50(2):320-31. PubMed ID: 24140268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
